Results 91 to 100 of about 99,253,553 (299)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

DPP-4 inhibitor restored level of p-ERK induced by 1 mM IS.

, 2014
Cells were exposed to 1 mM IS for 3 h and then treated with 100 ng/mL DPP-4 inhibitor. The treated cells were lysed for determination of p-ERK and ERK by immunoblot using specific antibodies and chemiluminescence development.
Chen-Hung Chang (586172), Mao-Feng Sun (586173), Wei-Jie Wang (186948), Sheng-Feng Hsu (586174), Ching-Sung Weng (586175)   +4 more
core   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

BMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jing‐Yi Zhu, Wei Xue   +6 more
wiley   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

, 2019
Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice ...
Toshihiko Yanase, Ryoko Motonaga, Takashi Fukuda, Takashi Nomiyama, Takeshi Horikawa, Yuriko Hamaguchi, Tomoko Tanaka, Makito Tanabe, Yuichi Terawaki, Hiroyuki Takahashi, Takako Kawanami   +10 more
core   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)

, 2015
Dipeptidyl peptidase 4 (DPP-4) enzymatically inactivates incretin hormones, and DPP-4 inhibitor drugs are clinically approved therapies for type 2 diabetes.
Panwar, Harsh, Calderwood, Danielle, Green, Brian D., Grover, Sunita, Grant, Irene R.; id_orcid   +4 more
core   +1 more source

Different from bone: Tooth formation and enameloid mineralization are not affected by reduced dietary phosphorus intake

Developmental Dynamics, EarlyView.
Abstract Background Vertebrates rely on phosphorus intake for skeletal mineralization. In humans, hypomineralized teeth associated with rickets, hypophosphatemia, hypophosphatasia, or idiopathic molar‐incisor‐hypomineralization pose significant problems.
S. Cotti, A. Huysseune, I. A. K. Fiedler, B. Busse, C. Di Biagio, M. Rücklin, F. Marone, A. Forlino, P. E. Witten   +8 more
wiley   +1 more source